Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators. Barbui T, et al. Haematologica. 2011 Feb;96(2):315-8. doi: 10.3324/haematol.2010.031070. Epub 2010 Dec 20. Haematologica. 2011. PMID: 21173097 Free PMC article.
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R. Rambaldi A, et al. Among authors: barbui t. Blood. 2002 Feb 1;99(3):856-62. doi: 10.1182/blood.v99.3.856. Blood. 2002. PMID: 11806987 Free article. Clinical Trial.
Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Bassan R, Lerede T, Borleri G, Chiodini B, Rossi A, Buelli M, Rambaldi A, Viero P, Barbui T. Bassan R, et al. Among authors: barbui t. Haematologica. 2002 Mar;87(3):257-63. Haematologica. 2002. PMID: 11869937 Clinical Trial.
Chronic myeloproliferative disorders.
Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M. Spivak JL, et al. Among authors: barbui t. Hematology Am Soc Hematol Educ Program. 2003:200-24. doi: 10.1182/asheducation-2003.1.200. Hematology Am Soc Hematol Educ Program. 2003. PMID: 14633783 Review.
Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Landolfi R, et al. Among authors: barbui t. N Engl J Med. 2004 Jan 8;350(2):114-24. doi: 10.1056/NEJMoa035572. N Engl J Med. 2004. PMID: 14711910 Free article. Clinical Trial.
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.
Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T; ECLAP Investigators. Finazzi G, et al. Among authors: barbui t. Blood. 2005 Apr 1;105(7):2664-70. doi: 10.1182/blood-2004-09-3426. Epub 2004 Dec 7. Blood. 2005. PMID: 15585653 Free article.
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R. Rambaldi A, et al. Among authors: barbui t. Blood. 2005 May 1;105(9):3428-33. doi: 10.1182/blood-2004-06-2490. Epub 2005 Jan 6. Blood. 2005. PMID: 15637137 Free article.
Idiopathic erythrocytosis and other non-clonal polycythemias.
Finazzi G, Gregg XT, Barbui T, Prchal JT. Finazzi G, et al. Among authors: barbui t. Best Pract Res Clin Haematol. 2006;19(3):471-82. doi: 10.1016/j.beha.2005.07.006. Best Pract Res Clin Haematol. 2006. PMID: 16781484 Review.
Evidence-based management of polycythemia vera.
Barbui T, Finazzi G. Barbui T, et al. Best Pract Res Clin Haematol. 2006;19(3):483-93. doi: 10.1016/j.beha.2005.07.007. Best Pract Res Clin Haematol. 2006. PMID: 16781485 Review.
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.
Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Landolfi R, et al. Among authors: barbui t. Blood. 2007 Mar 15;109(6):2446-52. doi: 10.1182/blood-2006-08-042515. Epub 2006 Nov 14. Blood. 2007. PMID: 17105814 Free article.
The haematocrit and platelet target in polycythemia vera.
Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, Leone G, Marfisi R, Porreca E, Ruggeri M, Rutjes AW, Tognoni G, Vannucchi AM, Marchioli R; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. Di Nisio M, et al. Among authors: barbui t. Br J Haematol. 2007 Jan;136(2):249-59. doi: 10.1111/j.1365-2141.2006.06430.x. Epub 2006 Dec 8. Br J Haematol. 2007. PMID: 17156406
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.
Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T; European Group for Blood and Marrow Transplantation; European LeukemiaNet. Ruutu T, et al. Among authors: barbui t. Haematologica. 2007 Jan;92(1):95-100. doi: 10.3324/haematol.10699. Haematologica. 2007. PMID: 17229640 Free article.
How I treat patients with polycythemia vera.
Finazzi G, Barbui T. Finazzi G, et al. Among authors: barbui t. Blood. 2007 Jun 15;109(12):5104-11. doi: 10.1182/blood-2006-12-038968. Epub 2007 Jan 30. Blood. 2007. PMID: 17264301 Free article. Review.
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T. Vannucchi AM, et al. Among authors: barbui t. Blood. 2007 Aug 1;110(3):840-6. doi: 10.1182/blood-2006-12-064287. Epub 2007 Mar 22. Blood. 2007. PMID: 17379742 Free article.
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A. Spinelli O, et al. Among authors: barbui t. Haematologica. 2007 May;92(5):612-8. doi: 10.3324/haematol.10965. Haematologica. 2007. PMID: 17488684 Free article.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Tefferi A, et al. Among authors: barbui t. Blood. 2007 Aug 15;110(4):1092-7. doi: 10.1182/blood-2007-04-083501. Epub 2007 May 8. Blood. 2007. PMID: 17488875 Free article.
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.
Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A. Introna M, et al. Among authors: barbui t, barbui am. Haematologica. 2007 Jul;92(7):952-9. doi: 10.3324/haematol.11132. Haematologica. 2007. PMID: 17606446 Free article. Clinical Trial.
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. Barosi G, et al. Among authors: barbui t. Blood. 2007 Dec 1;110(12):4030-6. doi: 10.1182/blood-2007-07-099184. Epub 2007 Aug 21. Blood. 2007. PMID: 17712047 Free article.
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.
Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Micò C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party. Ruggeri M, et al. Among authors: barbui t. Blood. 2008 Jan 15;111(2):666-71. doi: 10.1182/blood-2007-07-102665. Epub 2007 Oct 1. Blood. 2008. PMID: 17909074 Free article.
Thrombocytosis and thrombosis.
Vannucchi AM, Barbui T. Vannucchi AM, et al. Among authors: barbui t. Hematology Am Soc Hematol Educ Program. 2007:363-70. doi: 10.1182/asheducation-2007.1.363. Hematology Am Soc Hematol Educ Program. 2007. PMID: 18024652 Review.
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T; GIMEMA CMD-Working Party. De Stefano V, et al. Among authors: barbui t. Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268279 Free article.
Leukocytosis and risk stratification assessment in essential thrombocythemia.
Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T. Carobbio A, et al. Among authors: barbui t. J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. Epub 2008 Apr 28. J Clin Oncol. 2008. PMID: 18443353 Clinical Trial.
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T. Vannucchi AM, et al. Among authors: barbui t. Blood. 2008 Aug 1;112(3):844-7. doi: 10.1182/blood-2008-01-135897. Epub 2008 Jun 2. Blood. 2008. PMID: 18519816 Free article.
From palliation to epigenetic therapy in myelofibrosis.
Rambaldi A, Barbui T, Barosi G. Rambaldi A, et al. Among authors: barbui t. Hematology Am Soc Hematol Educ Program. 2008:83-91. doi: 10.1182/asheducation-2008.1.83. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074063 Review.
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Among authors: barbui t. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM. Guglielmelli P, et al. Among authors: barbui t. Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23. Blood. 2009. PMID: 19549988 Free article.
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party. De Stefano V, et al. Among authors: barbui t. Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7. Ann Hematol. 2010. PMID: 19582452
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, Carobbio A, Rambaldi A, Barbui T, Bassan R. Intermesoli T, et al. Among authors: barbui t. Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. Epub 2009 Sep 4. Br J Haematol. 2009. PMID: 19735261 Clinical Trial.
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D, Bosi A, Candoni A, Locasciulli A, Locatelli F, Menichetti F, Musso M, Viscoli C, Rambaldi A. Girmenia C, et al. Among authors: barbui t. Clin Infect Dis. 2009 Oct 15;49(8):1226-36. doi: 10.1086/605665. Clin Infect Dis. 2009. PMID: 19772390
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. Barosi G, et al. Among authors: barbui t. Br J Haematol. 2010 Mar;148(6):961-3. doi: 10.1111/j.1365-2141.2009.08019.x. Epub 2009 Nov 23. Br J Haematol. 2010. PMID: 19930182 Review. No abstract available.
Thrombosis in primary myelofibrosis: incidence and risk factors.
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Barbui T, et al. Blood. 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. Epub 2009 Nov 20. Blood. 2010. PMID: 19965680 Free article.
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party. De Stefano V, et al. Among authors: barbui t. Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593. Am J Hematol. 2010. PMID: 20052743 Free article.
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi AM. Antonioli E, et al. Among authors: barbui t. Haematologica. 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. Epub 2010 Apr 23. Haematologica. 2010. PMID: 20418246 Free PMC article. No abstract available.
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T. Rambaldi A, et al. Among authors: barbui t. Br J Haematol. 2010 Aug;150(4):446-55. doi: 10.1111/j.1365-2141.2010.08266.x. Epub 2010 Jun 15. Br J Haematol. 2010. PMID: 20560970 Clinical Trial.
Special issues in myeloproliferative neoplasms.
Barbui T, Finazzi G. Barbui T, et al. Curr Hematol Malig Rep. 2011 Mar;6(1):28-35. doi: 10.1007/s11899-010-0073-7. Curr Hematol Malig Rep. 2011. PMID: 21181458 Review.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Barbui T, et al. J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205761 Free PMC article.
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Carobbio A, et al. Among authors: barbui t. Blood. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13. Blood. 2011. PMID: 21490340 Free article.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. Scherber R, et al. Among authors: barbui t. Blood. 2011 Jul 14;118(2):401-8. doi: 10.1182/blood-2011-01-328955. Epub 2011 May 2. Blood. 2011. PMID: 21536863 Free article.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Guglielmelli P, et al. Among authors: barbui t. Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1. Blood. 2011. PMID: 21725052 Free PMC article. Clinical Trial.
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A. Barbui T, et al. J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747083
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.
Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Carobbio A, et al. Among authors: barbui t. Am J Hematol. 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. Epub 2012 Jan 11. Am J Hematol. 2012. PMID: 22237692 Free article.
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A. Barbui T, et al. Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13. Blood. 2012. PMID: 22246040 Free article.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. Harrison C, et al. Among authors: barbui t. N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. N Engl J Med. 2012. PMID: 22375970 Free article. Clinical Trial.
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R. Gowin K, et al. Among authors: barbui t. Haematologica. 2012 Oct;97(10):1570-3. doi: 10.3324/haematol.2011.061390. Epub 2012 Mar 14. Haematologica. 2012. PMID: 22419578 Free PMC article.
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Abdel-Wahab O, et al. Among authors: barbui t. Am J Hematol. 2012 May;87(5):562-8. doi: 10.1002/ajh.23169. Epub 2012 Mar 28. Am J Hematol. 2012. PMID: 22460584 Free PMC article.
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, De Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM; AGIMM Investigators. Antonioli E, et al. Among authors: barbui t. Am J Hematol. 2012 May;87(5):552-4. doi: 10.1002/ajh.23160. Epub 2012 Apr 4. Am J Hematol. 2012. PMID: 22473827 Free article.
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.
Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T. Buxhofer-Ausch V, et al. Among authors: barbui t. Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10. Am J Hematol. 2012. PMID: 22573503 Free article.
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.
Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A. Barbui T, et al. Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. Epub 2012 Jun 13. Blood. 2012. PMID: 22700720 Free article.
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. Passamonti F, et al. Among authors: barbui t. Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26. Blood. 2012. PMID: 22740446 Free article.
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Barbui T, et al. Blood. 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. Epub 2012 Oct 1. Blood. 2012. PMID: 23033268 Free article.
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Emanuel RM, et al. Among authors: barbui t. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. J Clin Oncol. 2012. PMID: 23071245 Free PMC article.
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. Among authors: barbui t. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Cilloni D, Sivera P, Barosi G, Finazzi MC, Tollo SD, Demuth T, Barbui T, Rambaldi A. Finazzi G, et al. Among authors: barbui t. Br J Haematol. 2013 Jun;161(5):688-694. doi: 10.1111/bjh.12332. Epub 2013 Apr 10. Br J Haematol. 2013. PMID: 23573950 Clinical Trial.
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Barosi G, et al. Among authors: barbui t. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16. Blood. 2013. PMID: 23591792 Free PMC article.
Treatment target in polycythemia vera.
Marchioli R, Vannucchi AM, Barbui T. Marchioli R, et al. Among authors: barbui t. N Engl J Med. 2013 Apr 18;368(16):1556. doi: 10.1056/NEJMc1301262. N Engl J Med. 2013. PMID: 23594012 No abstract available.
Myeloproliferative neoplasms and thrombosis.
Barbui T, Finazzi G, Falanga A. Barbui T, et al. Blood. 2013 Sep 26;122(13):2176-84. doi: 10.1182/blood-2013-03-460154. Epub 2013 Jul 3. Blood. 2013. PMID: 23823316 Free article. Review.
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Mesa RA, et al. Among authors: barbui t. Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2. Haematologica. 2014. PMID: 23911705 Free PMC article. Clinical Trial.
Masked polycythemia vera (mPV): results of an international study.
Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, Luigia Randi M, Bertozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A. Barbui T, et al. Am J Hematol. 2014 Jan;89(1):52-4. doi: 10.1002/ajh.23585. Epub 2013 Sep 19. Am J Hematol. 2014. PMID: 23996471 Free article.
Are MPNs vascular diseases?
Finazzi G, De Stefano V, Barbui T. Finazzi G, et al. Among authors: barbui t. Curr Hematol Malig Rep. 2013 Dec;8(4):307-16. doi: 10.1007/s11899-013-0176-z. Curr Hematol Malig Rep. 2013. PMID: 24037420 Review.
Masked polycythemia vera diagnosed according to WHO and BCSH classification.
Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A. Barbui T, et al. Am J Hematol. 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617. Am J Hematol. 2014. PMID: 24166817 Free article.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H; COMFORT-II investigators. Cervantes F, et al. Among authors: barbui t. Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30. Blood. 2013. PMID: 24174625 Free article. Clinical Trial.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Verstovsek S, et al. Among authors: barbui t. Cancer. 2014 Feb 15;120(4):513-20. doi: 10.1002/cncr.28441. Cancer. 2014. PMID: 24258498 Free PMC article. Clinical Trial.
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.
Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, Polverelli N, Ruggeri M, Vannucchi AM, Antonioli E, Lussana F, Tieghi A, Iurlo A, Elli E, Ruella M, Fabris F, Cazzola M, Barbui T. Randi ML, et al. Among authors: barbui t. Am J Hematol. 2014 Mar;89(3):306-9. doi: 10.1002/ajh.23635. Epub 2014 Feb 19. Am J Hematol. 2014. PMID: 24265194 Free article.
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M. Passamonti F, et al. Among authors: barbui t. Blood. 2014 Mar 20;123(12):1833-5. doi: 10.1182/blood-2013-12-544411. Epub 2014 Jan 17. Blood. 2014. PMID: 24443442 Free article. Clinical Trial.
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA. Geyer HL, et al. Among authors: barbui t. Blood. 2014 Jun 12;123(24):3803-10. doi: 10.1182/blood-2013-09-527903. Epub 2014 Feb 19. Blood. 2014. PMID: 24553173 Free PMC article.
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.
Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Pennucci V, et al. Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. Epub 2014 Jun 16. Leuk Lymphoma. 2015. PMID: 24707949 No abstract available.
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM. Mughal TI, et al. Among authors: barbui t. Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. Haematologica. 2014. PMID: 24790057 Free PMC article. Review. No abstract available.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1. Blood. 2014. PMID: 24986690 Free PMC article.
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM. Tefferi A, et al. Among authors: barbui t. Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18. Blood. 2014. PMID: 25037629 Free PMC article.
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortelezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T. Martinelli I, et al. Among authors: barbui t. Am J Hematol. 2014 Nov;89(11):E200-5. doi: 10.1002/ajh.23809. Epub 2014 Jul 31. Am J Hematol. 2014. PMID: 25042466 Free article.
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T. Lussana F, et al. Among authors: barbui t. Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16. Br J Haematol. 2014. PMID: 25130523 Clinical Trial.
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.
Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A. Barbui T, et al. Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27. Am J Hematol. 2015. PMID: 25683038 Free article.
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Geyer H, et al. Among authors: barbui t. J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598745 Free article.
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P. Rotunno G, et al. Among authors: barbui t. Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11. Am J Hematol. 2016. PMID: 27037840 Free article.
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.
Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM. Guglielmelli P, et al. Among authors: barbui t. Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4. Am J Hematol. 2016. PMID: 27264006 Free article.
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Geyer HL, et al. Among authors: barbui t. Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18. Haematologica. 2017. PMID: 27540137 Free PMC article.
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.
Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A. Barbui T, et al. Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. Am J Hematol. 2017. PMID: 27737508 Free article. Clinical Trial. No abstract available.
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T. Scherber RM, et al. Among authors: barbui t. Leuk Lymphoma. 2017 Jun;58(6):1481-1487. doi: 10.1080/10428194.2016.1246733. Epub 2016 Nov 10. Leuk Lymphoma. 2017. PMID: 27830999 Free PMC article.
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, Colagrande S, Castellani A, Masciulli A, Rosti V, De Stefano V, Betti S, Finazzi G, Ferrari ML, Rumi E, Ruggeri M, Nichele I, Guglielmelli P, Fjerza R, Mannarelli C, Fanelli T, Merli L, Corbizi Fattori G, Massa M, Cimino G, Rambaldi A, Barosi G, Cazzola M, Barbui T, Vannucchi AM. Pieri L, et al. Among authors: barbui t. Am J Hematol. 2017 Feb;92(2):187-195. doi: 10.1002/ajh.24614. Am J Hematol. 2017. PMID: 27880982 Free article. Clinical Trial.
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.
Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM. Barbui T, et al. Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. Haematologica. 2017. PMID: 28255021 Free PMC article. Review. No abstract available.
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group. Guglielmelli P, et al. Among authors: barbui t. Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28. Blood. 2017. PMID: 28351937 Free article. Clinical Trial.
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.
Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian JJ, Gianelli U, Silver R, Mughal TI, Barbui T. Kvasnicka HM, et al. Among authors: barbui t. Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28685840 Free article.
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Verstovsek S, et al. Among authors: barbui t. Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. Blood. 2017. PMID: 28827411 Free PMC article. Clinical Trial. No abstract available.
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL. Scotch AH, et al. Among authors: barbui t. Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14. Leuk Res. 2017. PMID: 29096334 Free PMC article.
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. Guglielmelli P, et al. Among authors: barbui t. J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9. J Clin Oncol. 2018. PMID: 29226763 Free article.
Essential thrombocythemia treatment algorithm 2018.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Among authors: barbui t. Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8. Blood Cancer J. 2018. PMID: 29321520 Free PMC article. Review.
Polycythemia vera treatment algorithm 2018.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Among authors: barbui t. Blood Cancer J. 2018 Jan 10;8(1):3. doi: 10.1038/s41408-017-0042-7. Blood Cancer J. 2018. PMID: 29321547 Free PMC article. Review.
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T. De Stefano V, et al. Among authors: barbui t. Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9. Blood Cancer J. 2018. PMID: 29535299 Free PMC article. Clinical Trial.
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: barbui t. Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. Haematologica. 2018. PMID: 29622658 Free PMC article. No abstract available.
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: barbui t. Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. Leuk Res. 2018. PMID: 29734070 No abstract available.
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F. Barraco D, et al. Among authors: barbui t. Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. Blood Cancer J. 2018. PMID: 30291232 Free PMC article. No abstract available.
Prefibrotic myelofibrosis: treatment algorithm 2018.
Finazzi G, Vannucchi AM, Barbui T. Finazzi G, et al. Among authors: barbui t. Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z. Blood Cancer J. 2018. PMID: 30405096 Free PMC article. Review.
Comments on pre-fibrotic myelofibrosis and how should it be managed.
Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A. Barbui T, et al. Br J Haematol. 2019 Jul;186(2):358-360. doi: 10.1111/bjh.15840. Epub 2019 Mar 7. Br J Haematol. 2019. PMID: 30847907 Free article. No abstract available.
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Barbui T, et al. Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29. Leukemia. 2019. PMID: 31142846
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F. Mora B, et al. Among authors: barbui t. Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7. Cancer Med. 2019. PMID: 31173472 Free PMC article.
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM. Loscocco GG, et al. Among authors: barbui t. Am J Hematol. 2019 Sep;94(9):E239-E242. doi: 10.1002/ajh.25555. Epub 2019 Jun 22. Am J Hematol. 2019. PMID: 31179561 Free article. No abstract available.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Yacoub A, et al. Among authors: barbui t. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. Blood. 2019. PMID: 31515250 Free PMC article. Clinical Trial.
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: barbui t. Am J Hematol. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1. Am J Hematol. 2020. PMID: 31588594 Free article. No abstract available.
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM. Sant'Antonio E, et al. Among authors: barbui t. Am J Hematol. 2020 Feb;95(2):156-166. doi: 10.1002/ajh.25677. Epub 2019 Nov 29. Am J Hematol. 2020. PMID: 31721282 Free article.
Second cancers in MPN: Survival analysis from an international study.
Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Marchetti M, et al. Among authors: barbui t. Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31816122 Free article. Clinical Trial.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. De Stefano V, et al. Among authors: barbui t. Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614. Blood. 2020. PMID: 31869407 Free article.
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T. Guglielmelli P, et al. Among authors: barbui t. Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2. Blood Cancer J. 2020. PMID: 32098944 Free PMC article.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Barbui T, et al. Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414483 Free PMC article.
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Lancet Haematol. 2021. PMID: 33476571 Clinical Trial.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Barbui T, et al. Blood Cancer J. 2021 Feb 4;11(2):21. doi: 10.1038/s41408-021-00417-3. Blood Cancer J. 2021. PMID: 33563901 Free PMC article.
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.
Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J. Barbui T, et al. Leukemia. 2021 Oct;35(10):2989-2993. doi: 10.1038/s41375-021-01279-1. Epub 2021 May 19. Leukemia. 2021. PMID: 34012132 Free PMC article. No abstract available.
Long-term follow-up of recovered MPN patients with COVID-19.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Barbui T, et al. Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. Blood Cancer J. 2021. PMID: 34135309 Free PMC article. No abstract available.
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T. Guglielmelli P, et al. Among authors: barbui t. Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. Blood Adv. 2022. PMID: 34753179 Free PMC article. No abstract available.
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.
Farrukh F, Guglielmelli P, Loscocco GG, Pardanani A, Hanson CA, De Stefano V, Barbui T, Gangat N, Vannucchi AM, Tefferi A. Farrukh F, et al. Among authors: barbui t. Am J Hematol. 2022 Feb 1;97(2):E35-E37. doi: 10.1002/ajh.26423. Epub 2021 Dec 6. Am J Hematol. 2022. PMID: 34822188 Free article. No abstract available.
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, Coltro G, Betti S, Maccari C, Ceglie S, Chiusolo P, Paoli C, Barbui T, Tefferi A, De Stefano V, Vannucchi AM. Guglielmelli P, et al. Among authors: barbui t. Blood Cancer J. 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6. Blood Cancer J. 2021. PMID: 34897288 Free PMC article.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: barbui t. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. Blood. 2022. PMID: 35007321 Free PMC article. Clinical Trial.
Second versus first wave of COVID-19 in patients with MPN.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Barbui T, et al. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21. Leukemia. 2022. PMID: 35064223 Free PMC article. No abstract available.
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events.
Gangat N, Szuber N, Jadoon Y, Farrukh F, Begna K, Elliott MA, Wolanskyj-Spinner AP, Hanson CA, Pardanani AD, De Stefano V, Barbui T, Vannucchi AM, Tefferi A. Gangat N, et al. Among authors: barbui t. Blood Adv. 2022 Jul 12;6(13):3835-3839. doi: 10.1182/bloodadvances.2022007023. Blood Adv. 2022. PMID: 35271689 Free PMC article. No abstract available.
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Marchetti M, et al. Among authors: barbui t. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. Lancet Haematol. 2022. PMID: 35358444 Review.
725 results